Skip to main navigation Skip to search Skip to main content

Erratum: Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness (Annals of oncology : official journal of the European Society for Medical Oncology (2012) 23 9 (2356-2362))

  • M. S. Czuczman
  • , J. P. Leonard
  • , S. Jung
  • , J. L. Johnson
  • , E. D. Hsi
  • , J. C. Byrd
  • , B. D. Cheson

Research output: Contribution to journal › Comment/debate

2   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Erratum: Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness (Annals of oncology : official journal of the European Society for Medical Oncology (2012) 23 9 (2356-2362))'. Together they form a unique fingerprint.
Sort by